This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk00: Ladies and gentlemen, thank you for standing by. And welcome to the Quarter 1, 2022 Vanda Pharmaceuticals Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 on your telephone. Please be advised that today's conference is being recorded. If you require any further assistance, please press star zero. I would now like to turn the call over to our speaker today, Kevin Moran, Vanda's Chief Financial Officer. Sir, you may begin.
spk02: Thank you, Marjorie. Good afternoon, and thank you for joining us to discuss Vanda Pharmaceuticals' first quarter 2022 performance. Our first quarter 2022 results were released this afternoon and are available on the SEC's EDGAR system and on our websites. www.vandafarma.com. In addition, we are providing live and archived versions of this conference call on our website. Joining me on today's call is Dr. Mahalas Paliamaropoulos, our President, Chief Executive Officer, and Chairman of the Board. Additionally, we have Tim Williams, our General Counsel, and Gunther Biersnix, our Senior Vice President of Business Development and R&D Committee Member. Following my introductory remarks, Mahalas will update you on our ongoing activities. I will then comment on our financial results before opening the lines for your questions. Before we proceed, I would like to remind everyone that various statements that we make on this call will be forward-looking statements within the meaning of federal securities laws. Our forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances, and uncertainties. These risks are described in the cautionary note regarding forward-looking statements, risk factors, and management's discussion and analysis of financial condition and results of operations, sections of our annual report on Form 10-K for the fiscal year ended December 31, 2021, as updated by our subsequent quarterly reports on Form 10-Q, current reports on Form 8-K, and other filings with the SEC, which are available on the SEC's EDGAR system and on our website. We encourage all investors to read these reports and our other filings. The information we provide on this call is provided only as of today, and we undertake no obligation to update or revise publicly any forward-looking statements we may make on this call on account of new information, future events, or otherwise, except as required by law. With that said, I would now like to turn the call over to our CEO, Dr. Mahalas Paliamaropoulos.
spk01: Thank you very much, Kevin. Good afternoon, everyone. Thank you for joining us today to discuss VANDIS, first quarter 2022 results. We believe 2022 is going to be an exciting year for the company, as we strengthen our commercial efforts and advance our clinical pipeline. Turning first to commercial performance. On HEPQS, challenges with payer denial for sight in patients with NON24 persist. However, we are progressing efforts with commercial payers, Medicare and Medicaid, to support patients and increase reimbursement approval rates. Since 2021, over 15 states have revised their Medicaid prior authorization criteria, eliminating the restriction of health use coverage on the basis of vision status for the treatment of non-24. At the same time, we see increase in the adoption of coverage for patients with nighttime sleep disturbances in Smith-McGenney syndrome, or SMS. We will continue to move this effort forward and are committed to working with all parties to improve coverage for our patients. On SMS, for the indication of nighttime sleep disturbances, we're seeing continued interest by patients and caregivers attributed to direct-to-consumer campaigns as we increase awareness around SMS and our ongoing work with advocacy organizations such as prisms. Other educational initiatives for SMS are underway. As previously noted, many patients with SMS remain undiagnosed and are currently treated for various neurodevelopmental disorders. Our genetics work has identified that among patients with autism, there is an increase in prevalence, of the RAI1 gene deletions and loss of functional mutations. This suggests that some patients diagnosed with autism may also have SMS. We're evaluating opportunities to engage with the autism community and elevate awareness of SMS among this population as well. On patent exclusivity for Hetlius, the product is currently covered by a number of patents, listed in the FDA's Orange Book with expeditions through 2035. In January, 2022, Banner settled its headless patent litigation against the MSN pharmaceuticals defendant. In March, 2022, the undertrial for the consolidated lawsuit against the remaining defendants was held. A decision is expected from the court by December 2022. The four patents that remain in the suit have expiration dates between 2033 and 2035. We remain confident in these patents and look forward to the court's decision. On the clinical pipeline front, we have a number of late-stage programs underway. First, I would like to offer an update on our most advanced program with the dividend In February, Vanda reported results of the Phase III study of tradipitin in gastroparesis and initial exploratory analysis. We have now completed a pooled analysis of two studies of tradipitin in gastroparesis consisting of a total of 342 patients and examined relevant clinical endpoints. We believe the studies are adequately well-controlled and the results support substantial evidence of efficacy of tradipitin. I refer you to the two figures and tables presented and included in today's press release. This large meta-analysis shows tradipitin to be superior to placebo in key clinical parameters, including improvement in nausea, the primary endpoint parameter, percent nausea-free days, the patient global impression scale change, The overall benefit score, the gastroparesis cardinal symptom index score. An open-label study of safety for tradipitin in gastroparesis is ongoing. We continue to receive requests from patients interested in gaining access to tradipitin through the expanded access program. Multiple patients in the expanded access program have been taking tradipitin now for more than a year with the longest having been on tradiptin for over 18 months. Vander has now scheduled a pre-NDA meeting with the FDA to discuss the planned new drug application submission for tradiptin in the short term, treatment of nausea in gastroparesis, and is committed to delivering this much-needed treatment for patients. In addition, the phase three study in the prevention of motion sickness has resumed enrollment and is already over 15% enrolled. A prior Phase II study with tradipitin in motion sickness observed a significantly lower incidence of vomiting in patients treated with tradipitin as compared to placebo-treated patients. We expect enrollment to be complete by the end of 2022. Enrollment is also ongoing in the clinical development programs of HEPLEOS, for the treatment of delayed sleep phase disorder and for symptoms of autism spectrum disorder. Finally, our phase three clinical study of FNAPT in acute manic episodes in patients with bipolar disorder is progressing and is now over 75% enrolled. We expect to complete enrollment by the end of 2022. To conclude, we expect 2022 to be a year with significant milestones as we advance a number of clinical programs towards new indications. On that note, I will turn now the call over to Kevin to discuss the first quarter 2022 financials. Kevin.
spk02: Thank you, Miles. I'll begin by summarizing our first quarter 2022 financial results. Total revenues for the first quarter of 2022 were $60.2 million, a 4% decrease compared to $62.7 million for the first quarter of 2021. Hetlios net product sales were $37 million for the first quarter of 2022, compared to $39.3 million in the first quarter of 2021. Consistent with prior years and expectations, the first quarter 2022 Hetlios revenue was impacted by the annual Medicare manufacturer contribution and the annual payer disruption linked to new plan years, plan changes, and reauthorizations, which we have seen in prior years. Additionally, the first quarter of 2022 reflects the continued and significant increase of reimbursement challenges from payers to fill Hetlios prescriptions for patients with non-24. Turning to FINAP. FINAP net product sales in the first quarter of 2022 were $23.2 million, essentially flat as compared to $23.3 million in the first quarter of 2021. FNAPT net product sales in the first quarter of 2022 decreased by 3% as compared to $24 million in the fourth quarter of 2021. FNAPT prescriptions in the first quarter of 2022, as reported by Equivia Exponent, decreased by approximately 2% compared to the fourth quarter of 2021. This decrease is consistent with the performance of FNAPT we've seen in the first quarter of prior years. For the first quarter of 2022, Vanda recorded a net loss of 6.4 million compared to net income of 8.7 million for the first quarter of 2021. The net loss for the first quarter of 2022 included an income tax benefit of 1.1 million as compared to an income tax provision of 1.8 million for the same period in 2021. Operating expenses in the first quarter of 2022 were 67.9 million compared to 52.3 million in the first quarter of 2021. The $15.5 million increase was primarily driven by higher expenses associated with the support of the Hetlios franchise, legal support related to ongoing litigation, awareness DTC campaigns, and other corporate expenses, as well as higher R&D expenses related to the late stage FNAP development program. Operating expenses in the first quarter of 2022 were $8.5 million higher as compared to $59.4 million in the fourth quarter of 2021. This increase was primarily attributable to higher expenses associated with support of the Hetlios franchise, legal support-related ongoing litigation, and other corporate expenses. Vanda's cash, cash equivalents, and marketable securities, referred to as cash, as of March 31, 2022, were $435.2 million, representing an increase of $57 million compared to March 31, 2021, and an increase of $2.4 million compared to December 31, 2021. Vanda expects to achieve the following financial objectives in 2022. Net product sales from both Hetlios and FNAPT of between $240 and $280 million. Hetlios net product sales of between $150 and $180 million. FNAPT net product sales of between $90 and $100 million. Year-end 2022 cash of greater than $440 million. With that, I'll now turn the call back to Mahalik.
spk01: Thank you very much, Kevin. At this point, we would be happy to answer any questions you may have.
spk00: As a reminder, to ask a question, you will need to press star 1 on your telephone. To answer your question, press the pound key. Please stand by while we compile the Q&A roster. There are no questions at this time. Please continue vendor management for closing remarks.
spk01: Thank you very much, and thank you all for joining us. We'll talk to you in the near future. Thank you.
spk00: Ladies and gentlemen, this concludes today's conference call. Thank you everyone for participating. You may now
Disclaimer